Malaria transmission blocking compounds: a patent review

References

• World malaria report 2021 [Internet]. cited 2022 Jan 31]. Available from 2022 Jan 31: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021.
   Google Scholar
• Gonçalves D, Hunziker P. Transmission-blocking strategies: the roadmap from laboratory bench to the community. Malar J. 2016;15:95.
   PubMed Web of Science ®Google Scholar
• Chawla J, Oberstaller J, Adams JH. Targeting gametocytes of the malaria parasite Plasmodium falciparum in a functional genomics era: next steps. Pathogens. 2021;10:346.
   PubMed Web of Science ®Google Scholar
• Dantzler KW, Ravel DB, Brancucci NM, et al. Ensuring transmission through dynamic host environments: host-pathogen interactions in plasmodium sexual development. Curr Opin Microbiol. 2015;26:17–23.
   PubMed Web of Science ®Google Scholar
• Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377–410.
   PubMed Web of Science ®Google Scholar
• Sinha A, Hughes KR, Modrzynska KK, et al. A cascade of DNA-binding proteins for sexual commitment and development in plasmodium. Nature. 2014;507:253–257.
   PubMed Web of Science ®Google Scholar
• Phillips MA, Burrows JN, Manyando C, et al. Malaria. Nat Rev Dis Primers. 2017;3:1–24.
   Web of Science ®Google Scholar
• Doerig C, Rayner JC, Scherf A, et al. Post-translational protein modifications in malaria parasites. Nat Rev Microbiol. 2015;13:160–172.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–211.
   PubMed Web of Science ®Google Scholar
• Balikagala B, Fukuda N, Ikeda M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163–1171.
   PubMed Web of Science ®Google Scholar
• Unwin HJT, Mwandigha L, Winskill P, et al. Analysis of the potential for a malaria vaccine to reduce gaps in malaria intervention coverage. Malar J. 2021;20:438.
   PubMed Web of Science ®Google Scholar
• Samarasekera U. Cautious optimism for malaria vaccine roll-out. Lancet. 2021;398:1394.
   PubMed Web of Science ®Google Scholar
• Lancet T. The lancet. malaria vaccine approval: a step change for global health. Lancet. 2021;398:1381.
   PubMed Web of Science ®Google Scholar
• Nkumama IN, Osier FHA. Malaria vaccine roller coaster. Nat Microbiol. 2021;6:1345–1346.
   PubMed Web of Science ®Google Scholar
• Leroy D, Campo B, Ding XC, et al. Defining the biology component of the drug discovery strategy for malaria eradication. Trends Parasitol. 2014;30:478–490.
   PubMed Web of Science ®Google Scholar
• malERA refresh consultative panel on tools for malaria elimination. malERA: an updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication. PLoS Med. 2017;14:e1002455.
   PubMed Web of Science ®Google Scholar
• Sinden RE. Developing transmission-blocking strategies for malaria control. PLoS Pathog. 2017;13:e1006336.
   PubMed Web of Science ®Google Scholar
• Nilsson SK, Childs LM, Buckee C, et al. Targeting human transmission biology for malaria elimination. PLoS Pathog. 2015;11:e1004871.
   PubMed Web of Science ®Google Scholar
• Sinden RE. Targeting the parasite to suppress malaria transmission. Adv Parasitol. 2017;97:147–185.
   PubMed Web of Science ®Google Scholar
• Chang -H-H, Hartl DL. Recurrent bottlenecks in the malaria life cycle obscure signals of positive selection. Parasitology. 2015;142:S98–S107.
   PubMed Web of Science ®Google Scholar
• Delves MJ, Miguel-Blanco C, Matthews H, et al. A high throughput screen for next-generation leads targeting malaria parasite transmission. Nat Commun. 2018;9:3805–3818.
   PubMed Web of Science ®Google Scholar
• Smith RC, Vega-Rodríguez J, Jacobs-Lorena M. The Plasmodium bottleneck: malaria parasite losses in the mosquito vector. Mem Inst Oswaldo Cruz. 2014;109:644–661.
   PubMed Web of Science ®Google Scholar
• Ross A, Brancucci NM. On a mission to block transmission. Elife. 2018;7:e35246.
   PubMed Web of Science ®Google Scholar
• Ippolito MM, Moser KA, Kabuya J-B-B, et al. Antimalarial drug resistance and implications for the WHO global technical strategy. Curr Epidemiol Rep. 2021;8:46–62.
   PubMedGoogle Scholar
• Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 2020;13:4047–4060.
   PubMed Web of Science ®Google Scholar
• Verlinden BK, Louw A, Birkholtz L-M. Resisting resistance: is there a solution for malaria? Expert Opin Drug Discov. 2016;11:395–406.
   PubMed Web of Science ®Google Scholar
• Pollitt LC, Huijben S, Sim DG, et al. Rapid response to selection, competitive release and increased transmission potential of artesunate-selected Plasmodium chabaudi malaria parasites. PLoS Pathog. 2014;10:e1004019.
   PubMed Web of Science ®Google Scholar
• Beshir KB, Sutherland CJ, Sawa P, et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis. 2013;208:2017–2024.
   PubMed Web of Science ®Google Scholar
• Goodman CD, Siregar JE, Mollard V, et al. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science. 2016;352:349–353.
   PubMed Web of Science ®Google Scholar
• Achan J, Mwesigwa J, Edwin CP, et al. Malaria medicines to address drug resistance and support malaria elimination efforts. Expert Rev Clin Pharmacol. 2018;11:61–70.
   PubMed Web of Science ®Google Scholar
• Witmer K, Dahalan FA, Delves MJ, et al. Transmission of artemisinin-resistant malaria parasites to mosquitoes under antimalarial drug pressure. Antimicrob Agents Chemother. 2021;65:e00898–20.
   Web of Science ®Google Scholar
• Durvasula R. Taking a bite out of mosquitoes: a new drug to block transmission of malaria. J Infect Dis. 2014;209:177–179.
   PubMed Web of Science ®Google Scholar
• Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines. 2020;5:48.
   PubMed Web of Science ®Google Scholar
• Blagborough AM, Churcher TS, Upton LM, et al. Transmission-blocking interventions eliminate malaria from laboratory populations. Nat Commun. 2013;4:1812–1819.
   PubMed Web of Science ®Google Scholar
• Bretscher MT, Griffin JT, Ghani AC, et al. Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment. Malar J. 2017;16:341.
   PubMedGoogle Scholar
• Lelièvre J, Almela MJ, Lozano S, et al. Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence “transmission blocking” assay. PLoS One. 2012;7:e35019.
   PubMed Web of Science ®Google Scholar
• Reader J, Botha M, Theron A, et al. Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. Malar J. 2015;14:213.
   PubMed Web of Science ®Google Scholar
• Plouffe DM, Wree M, Du AY, et al. High-Throughput assay and discovery of small molecules that interrupt malaria transmission. Cell Host Microbe. 2016;19:114–126.
   PubMed Web of Science ®Google Scholar
• Delves M, Plouffe D, Scheurer C, et al. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 2012;9:e1001169.
   PubMed Web of Science ®Google Scholar
• Fowler RE, Sinden RE, Pudney M. Inhibitory activity of the anti-malarial atovaquone (566C80) against ookinetes, oocysts, and sporozoites of Plasmodium berghei. J Parasitol. 1995;81:452–458.
   PubMed Web of Science ®Google Scholar
• Wadi I, Nath M, Anvikar AR, et al. Recent advances in transmission-blocking drugs for malaria elimination. Future Med Chem. 2019;11:3047–3088.
   PubMed Web of Science ®Google Scholar
• Wadi I, Singh P, Nath M, et al. Malaria transmission-blocking drugs: implications and future perspectives. Future Med Chem. 2020;12:1071–1101.
   PubMed Web of Science ®Google Scholar
• Ashton TD, Devine SM, Möhrle JJ, et al. The Development process for discovery and clinical advancement of modern antimalarials. J Med Chem. 2019;62:10526–10562.
   PubMed Web of Science ®Google Scholar
• Yipsirimetee A, Chiewpoo P, Tripura R, et al. Assessment in vitro of the antimalarial and transmission blocking activities of cipargamin and Ganaplacide in artemisinin resistant Plasmodium falciparum. Antimicrob Agents Chemother. 2022 cited on 2022 Jan 31. https://doi.org/10.1128/AAC.01481-21.
   Google Scholar
• McCarthy JS, Abd-Rahman AN, Collins KA, et al. Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum. Antimicrob Agents Chemother. 2021;65:e01423–20.
   PubMed Web of Science ®Google Scholar
• Birkholtz L-M, Coetzer TL, Mancama D, et al. Discovering new transmission-blocking antimalarial compounds: challenges and opportunities. Trends Parasitol. 2016;32:669–681.
   PubMed Web of Science ®Google Scholar
• Shaw WR, Marcenac P, Catteruccia F. Plasmodium development in Anopheles: a tale of shared resources. Trends Parasitol. 2022;38:124–135.
   PubMed Web of Science ®Google Scholar
• Monastyrskyi A, Kyle DE, Manetsch R. 4(1H)-pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities. Curr Top Med Chem. 2014;14:1693–1705.
   PubMed Web of Science ®Google Scholar
• Sullivan DJ. Quinolines block every step of malaria heme crystal growth. Proc Natl Acad Sci U S A. 2017;114:7483–7485.
   PubMed Web of Science ®Google Scholar
• Kapishnikov S, Staalsø T, Yang Y, et al. Mode of action of quinoline antimalarial drugs in red blood cells infected by Plasmodium falciparum revealed in vivo. Proc Natl Acad Sci U S A. 2019;116:22946–22952.
   PubMed Web of Science ®Google Scholar
• Pinheiro L CS, Feitosa L M, Gandi M O, et al. The development of novel compounds against malaria: quinolines, triazolpyridines, pyrazolopyridines and pyrazolopyrimidines. Molecules. 2019;24:E4095.
   PubMed Web of Science ®Google Scholar
• Herraiz T, Guillén H, González-Peña D, et al. Antimalarial quinoline drugs inhibit β-hematin and increase free hemin catalyzing peroxidative reactions and inhibition of cysteine proteases. Sci Rep. 2019;9:15398.
   PubMed Web of Science ®Google Scholar
• Sun W, Tanaka TQ, Magle CT, et al. Chemical signatures and new drug targets for gametocytocidal drug development. Sci Rep. 2014;4:3743.
   PubMed Web of Science ®Google Scholar
• Mckew JC, Zheng W, Williamson KC, et al. Method of blocking transmission of malarial parasite. WO2015073804. 2015 May 2021.
   Google Scholar
• Mckew JC, Zheng W, Williamson KC, et al. Method of blocking transmission of malarial parasite. US20160264570. 2016 Sep 15.
   Google Scholar
• Tanaka TQ, Williamson KC. A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue. Mol Biochem Parasitol. 2011;177:160–163.
   PubMed Web of Science ®Google Scholar
• Tanaka TQ, Dehdashti SJ, Nguyen D-T, et al. A quantitative high throughput assay for identifying gametocytocidal compounds. Mol Biochem Parasitol. 2013;188:20–25.
   PubMed Web of Science ®Google Scholar
• Krishnan K, Ziniel P, Li H, et al. Torin 2 derivative, NCATS-SM3710, has potent multistage antimalarial activity through inhibition of P. falciparum phosphatidylinositol 4-kinase (Pf PI4KIIIβ). ACS Pharmacol Transl Sci. 2020;3:948–964.
   PubMedGoogle Scholar
• Huang W, Li H, Sun W, et al. Compounds and method for blocking transmission of malarial parasite. WO2018071836 2018 Apr 19.
   Google Scholar
• Luo Z, Shah P, Sanderson PE, et al. Quinoline compounds and their preparation and use as antimalarial agents. WO2019217957. Nov 14 2019
   Google Scholar
• Patel PR, Sun W, Kim M, et al. In vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents. Bioorg Med Chem Lett. 2016;26:2907–2911.
   PubMed Web of Science ®Google Scholar
• Li H, Sun W, Huang X, et al. Efficient synthesis of 1,9-substituted benzo[h][1,6]naphthyridin-2(1h)-ones and evaluation of their Plasmodium falciparum gametocytocidal activities. ACS Comb Sci. 2017;19:748–754.
   PubMed Web of Science ®Google Scholar
• Chakrabarti D, Yuan Y, Huang G, et al. Antimalarial compounds. WO2020/206252 2020 Oct 8.
   Google Scholar
• Hermkens PHH, Schalkwijk J, Jansen PAM, et al. Pantothenamide analogues. WO2016072854. 2016 May 12.
   Google Scholar
• Hermkens PHH, Schalkwijk J, Jansen PAM, et al. Pantothenamide analogues. EP3215496B1. 2020 Jul 01.
   Google Scholar
• Tay WJD, Preiser PR, Tan CH, et al. Compounds having antimalarial activity. WO2020263191. 2020 Dec 30.
   Google Scholar
• Comer E, Munoz B, Beaudoin J, et al. Compounds for the treatment of malaria. WO2015002755. 2015 Jan 8.
   Google Scholar
• Guy RK, Hammill JT, Floyd D, et al. New anti-malarial agents. WO2021204952. 2021 Oct 14.
   Google Scholar
• Cassera MB, Carlier BM, Ding S, et al. Antimalarial compounds and uses thereof. WO2021195603. 2021 Sept 30.
   Google Scholar
• Huang G, Murillo Solano C, Melendez J, et al. Synthesis, structure-activity relationship, and antimalarial efficacy of 6-chloro-2-arylvinylquinolines. J Med Chem. 2020;63:11756–11785.
   PubMed Web of Science ®Google Scholar
• Guy RK, Zhu F, Guiguemde WA, et al. Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies.WO2013027196 2013 Feb 28.
   Google Scholar
• Gaur AH, McCarthy JS, Panetta JC, et al. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infect Dis. 2020;20:964–975.
   PubMed Web of Science ®Google Scholar
• Duffy PE. Transmission-blocking vaccines: harnessing herd immunity for malaria elimination. Expert Rev Vaccines. 2021;20:185–198.
   PubMed Web of Science ®Google Scholar
• Takashima E, Tachibana M, Morita M, et al. Identification of novel malaria transmission-blocking vaccine candidates. Front Cell Infect Microbiol. 2021;11:805482.
   PubMed Web of Science ®Google Scholar
• King CR, Wu Y, Plieskatt JL, et al. Malaria transmission-blocking vaccines. WO2021192393. 2021 sep 30.
   Google Scholar
• Singh SK, Thrane S, Chourasia BK, et al. Pfs230 and Pfs48/45 fusion proteins elicit strong transmission-blocking antibody responses against Plasmodium falciparum. Front Immunol. 2019;10:1256.
   PubMed Web of Science ®Google Scholar
• Singh SK, Theisen M. Multivalent malaria transmission-blocking vaccines. WO2020201191. 2020 Oct 8.
   Google Scholar
• Guirakhoo F, Domi A, Mccurley N. Methods and compositions for generating an immune response to treat or prevent malaria. WO2019060356. 2019 Mar 28.
   Google Scholar
• Boes A, Spiegel H, Edgu G, et al. Multi-component-multistage malaria vaccine. EP-2923709. 2015 Sept 30.
   Google Scholar
• Spiegel H, Boes A, Edgu G, et al. Three-component-multistage malaria vaccine. WO-2016037916.2016 March 17.
   Google Scholar
• Keleta Y, Ramelow J, Cui L, et al. Molecular interactions between parasite and mosquito during midgut invasion as targets to block malaria transmission. NPJ Vaccines. 2021;6:140.
   PubMed Web of Science ®Google Scholar
• Schneerson R, Kubler-Kielb J, Wu Y, et al. Conjugates of Plasmodium falciparum surface proteins as malaria vaccines. US20150050314. 2015 Feb 19.
   Google Scholar
• Barillas-Mury CV, Molina-Cruz A, Canepa GE. Compositions and methods for blocking transmission of Plasmodium. WO2018157083. 2018 Aug 30.
   Google Scholar
• Tabayashi N, Gotanda T, Sasaki H, et al. Malaria propagation-blocking vaccine. WO2018043741 2018.
   Google Scholar
• Pradel G, Simon N, Fischer R, et al. Novel malaria transmission-blocking vaccines. US20150191518A1. 2015 Jul 9.
   Google Scholar
• Li J. Immunogenic compositions and methods for blocking transmission of malaria. WO2016073364. 2016 May 12.
   Google Scholar
• Li J, Wang X, Zhang G, et al. Genome-block expression-assisted association studies discover malaria resistance genes in Anopheles gambiae. Proc Natl Acad Sci U S A. 2013;110:20675–20680.
   PubMed Web of Science ®Google Scholar
• Zhang G, Niu G, Franca CM, et al. Anopheles midgut frep1 mediates Plasmodium invasion. J Biol Chem. 2015;290:16490–16501.
   PubMed Web of Science ®Google Scholar
• Dong Y, Simões ML, Marois E, et al. CRISPR/Cas9 -mediated gene knockout of Anopheles gambiae FREP1 suppresses malaria parasite infection. PLoS Pathog. 2018;14:e1006898.
   PubMed Web of Science ®Google Scholar
• Niu G, Wang B, Zhang G, et al. Targeting mosquito FREP1 with a fungal metabolite blocks malaria transmission. Sci Rep. 2015;5:14694.
   PubMed Web of Science ®Google Scholar
• Niu G, Franc AC, Zhang G, et al. The fibrinogen-like domain of FREP1 protein is a broad-spectrum malaria transmission-blocking vaccine antigen. J Biol Chem. 2017;292:11960–11969.
   PubMed Web of Science ®Google Scholar
• Zhang G, Niu G, Perez L, et al. Malaria transmission assisted by interaction between Plasmodium α -tubulin-1 and Anopheles FREP1 protein [Internet]. Cited 2022 Jan 31] Available from 2022 Jan 31: http://biorxiv.org/lookup/doi/https://doi.org/10.1101/2019.12.16.878082.
   Google Scholar
• Li J. Vaccines against malaria transmission. US20210128711. 2021 May 6.
   Google Scholar
• Wadi I, Anvikar AR, Nath M, et al. Critical examination of approaches exploited to assess the effectiveness of transmission-blocking drugs for malaria. Future Med Chem. 2018;10:2619–2639.
   PubMed Web of Science ®Google Scholar
• Delves MJ, Angrisano F, Blagborough AM. Antimalarial transmission-blocking interventions: past, present, and future. Trends Parasitol. 2018;34:735–746.
   PubMed Web of Science ®Google Scholar
• Catteruccia F. Malaria-carrying mosquitoes get a leg up on insecticides. Nature. 2020;577:319–320.
   PubMed Web of Science ®Google Scholar
• Tokuda M, Arai M, Okuma K. Malaria transmission prevention agent having rare sugar as effective component thereof and malarial parasite growth regulating agent. EP3124028. 2017 Feb 01.
   Google Scholar
• Minetti C, Ingham VA, Ranson H. Effects of insecticide resistance and exposure on Plasmodium development in Anopheles mosquitoes. Curr Opin Insect Sci. 2020;39:42–49.
   PubMed Web of Science ®Google Scholar
• Paton DG, Childs LM, Itoe MA, et al. Exposing Anopheles mosquitoes to antimalarials blocks Plasmodium parasite transmission. Nature. 2019;567:239–243.
   PubMed Web of Science ®Google Scholar
• Catteruccia F, Paton DG. Method for reducing parasite burden in a mosquito. WO2020051130. 2020 Mar 12.
   Google Scholar
• Buchanan HD, McFadden GI, Goodman CD. Bed nets, insecticides, and antimalarials: where to next? Trends Parasitol. 2019;35:668–670.
   PubMed Web of Science ®Google Scholar
• McKeage K, Scott LJ. Atovaquone/Proguanil. Drugs. 2003;63:597–623.
   PubMed Web of Science ®Google Scholar
• Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4’-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol. 1992;43:1545–1553.
   PubMed Web of Science ®Google Scholar
• Boysen KE, Matuschewski K. Arrested oocyst maturation in Plasmodium parasites lacking type II NADH:Ubiquinone Dehydrogenase. J Biol Chem. 2011;286:32661–32671.
   PubMed Web of Science ®Google Scholar
• Ke H, Ganesan SM, Dass S, et al. Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages. PLoS One. 2019;14:e0214023.
   PubMed Web of Science ®Google Scholar
• Hino A, Hirai M, Tanaka TQ, et al. Critical roles of the mitochondrial complex II in oocyst formation of rodent malaria parasite Plasmodium berghei. J Biochem. 2012;152:259–268.
   PubMed Web of Science ®Google Scholar
• Sturm A, Mollard V, Cozijnsen A, et al. Mitochondrial ATP synthase is dispensable in blood-stage Plasmodium berghei rodent malaria but essential in the mosquito phase. Proc Natl Acad Sci U S A. 2015;112:10216–10223.
   PubMed Web of Science ®Google Scholar
• Parker JEA, Angarita-Jaimes N, Abe M, et al. Infrared video tracking of Anopheles gambiae at insecticide-treated bed nets reveals rapid decisive impact after brief localised net contact. Sci Rep. 2015;5:13392.
   PubMed Web of Science ®Google Scholar
• Reader J, van der Watt ME, Taylor D, et al. Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV pandemic response box. Nat Commun. 2021;12:269.
   PubMed Web of Science ®Google Scholar
• Malebo HM, D’Alessandro S, Ebstie YA, et al. In vitro multistage malaria transmission blocking activity of selected malaria box compounds. Drug Des Devel Ther. 2020;14:1593–1607.
   PubMed Web of Science ®Google Scholar
• Leshabane M, Dziwornu GA, Coertzen D, et al. Benzimidazole derivatives are potent against multiple life cycle stages of Plasmodium falciparum malaria parasites. ACS Infect Dis. 2021;7:1945–1955.
   PubMed Web of Science ®Google Scholar
• Le Manach C, Dam J, Woodland JG, et al. Identification and profiling of a novel diazaspiro[3.4]octane chemical series active against multiple stages of the human malaria parasite Plasmodium falciparum and optimization efforts. J Med Chem. 2021;64:2291–2309.
   PubMed Web of Science ®Google Scholar
• Coertzen D, Reader J, van der Watt ME, et al. Exploring the transmission-blocking activity of antiplasmodial 3,6-diarylated imidazopyridazines. Trans R Soc South Africa. 2021; 10: 225–233.
   Google Scholar
• Coelho CH, Rappuoli R, Hotez PJ, et al. Transmission-blocking vaccines for malaria: time to talk about vaccine introduction. Trends Parasitol. 2019;35:483–486.
   PubMed Web of Science ®Google Scholar